Form 4: Neurogene President and CFO Christine Cvijic Sells Shares

Neurogene Inc. President and CFO Christine Mikail Cvijic sold 9,600 shares of common stock via a pre-arranged 10b5-1 trading plan.

Summary

• Christine Mikail Cvijic, President and CFO of Neurogene Inc., executed the sale of 9,600 shares of common stock on May 6, 2026.
• The sales were conducted in two tranches of 4,800 shares each.
• The first tranche was sold at a weighted average price of $30.0732 per share.
• The second tranche was sold at a weighted average price of $32.4358 per share.
• The transactions were executed pursuant to a Rule 10b5-1 trading plan adopted on August 18, 2025.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as the sale was executed through a pre-planned 10b5-1 arrangement, which is standard practice for executive financial management.

Positives

• The sale was conducted under a pre-established 10b5-1 plan, which is a standard mechanism for executives to sell shares without triggering insider trading concerns.

Negatives

• The sale represents a reduction in the executive's direct equity stake in the company.

Risks

• Insider selling can sometimes be perceived negatively by the market as a signal of management's view on the company's valuation or future prospects.

Future Outlook

No specific forward-looking guidance regarding company operations was provided in this filing.

Industry Context

StockSavvy.ai notes that executive stock sales under 10b5-1 plans are common in the biotechnology sector and are typically viewed as routine liquidity events rather than indicators of operational performance.

Comparison to Industry Standards

• The use of 10b5-1 plans is the industry standard for corporate officers to manage personal financial planning while maintaining compliance with SEC regulations.

Stakeholder Impact

• Minimal impact expected as the sale was pre-planned and represents a small portion of the executive's total holdings.

Next Steps

• Future vesting of restricted stock units scheduled for 2027, 2028, and 2029.

Key Dates

Keywords

Neurogene, NGNE, Insider Trading, Form 4, Biotech, Executive Compensation